2009-10-29 09:08:03 -

Micrus Endovascular Corporation (Nasdaq: MEND) today announced that it will release financial results for the quarter ended September 30, 2009 before market open on Thursday, November 5, 2009. Micrus’ management will host an investment community conference call at 10:30 a.m. Eastern time (7:30 a.m. Pacific time) to discuss those results and answer questions.

Individuals interested in participating in the conference call

may do so by dialing (888) 803-8296 for domestic callers, or (706) 679-0753 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company’s Web site at www.micruscorp.com : .

A telephone replay will be available for 48 hours following the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 32806729.

A webcast replay will be available for 30 days by visiting the Investor Relations section on the Micrus Web site.



About Micrus Endovascular Corporation

Micrus develops, manufactures and markets implantable and disposable medical devices for use in the treatment of cerebral vascular diseases.

Micrus products are used by interventional neuroradiologists, interventional neurologists and neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke. Hemorrhagic and ischemic stroke are both significant causes of death and disability worldwide. The Micrus product lines enable physicians to gain access to the brain in a minimally invasive manner through the vessels of the arterial system. Micrus’ proprietary, three-dimensional microcoils anatomically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells stents, balloon catheters, access devices such as guide catheters, microcatheters, guidewires and accessory products used in conjunction with its microcoils. For more information, visit www.micruscorp.com : .



Company Contact:Micrus Endovascular CorporationGordon

Sangster ( gsangster@MicrusCorp.com : mailto:gsangster@MicrusCorp.com )Chief

Financial Officer(408) 433-1400orInvestor Contact:Lippert/Heilshorn
& Associates, Inc.Jody Cain ( jcain@lhai.com : mailto:jcain@lhai.com )Bruce

Voss ( bvoss@lhai.com : mailto:bvoss@lhai.com )(310)

691-7100